Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.

Nébié, Issa; Edwards, Nj J.; Tiono, Alfred B.; Ewer, Kj J.; Sanou, Gs S.; Soulama, Issiaka; Sanon, Souleymane; Diarra, Amidou; Yaro, Jb B.; Kangoye, David; Imoukhuede, Eb B.; Hill, Av V. S.; Sirima, Sb B.

Tools

Export citation

Search in Google Scholar

Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.

Journal article published in 2014 by Issa Nébié, Nj J. Edwards

, Alfred B. Tiono, Kj J. Ewer, Gs S. Sanou, Issiaka Soulama

, Souleymane Sanon, Amidou Diarra, Jb B. Yaro, David Kangoye, Eb B. Imoukhuede, Av V. S. Hill, Sb B. Sirima

This paper is available in a repository.

Full text: Download

Preprint: policy unknown

Upload

Postprint: policy unknown

Upload

Published version: policy unknown

Upload

Abstract

Prior to a chimpanzee adenovirus-based (ChAd63) malarial vaccine trial, sera were collected to assess ChAd63-specific neutralizing antibody titers in Banfora (Burkina Faso). The low neutralizing antibody titers reported in both adults and children (median titers, 139.1 and 35.0, respectively) are encouraging for the potential use of ChAd63 as a malarial vaccine vector.

Links

Tools

Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.

Abstract